We are happy to share the latest Community Statement issued by Biogen about the Phase 2/3 DEVOTE study evaluating the safety and efficacy of a higher dose regimen of nusinersen for the treatment of spinal muscular atrophy (SMA).
We are happy to share the latest Community Letter issued by Roche, after the Cure SMA Conference.
We are happy to share the latest Community Letter issued by Roche.
We are pleased to announce that, in response to our standing request for important SMA clinical development and programme updates, Roche has shared an update on the RAINBOWFISH clinical trial, for which results from the primary analysis were presented at the 28th World Muscle Society (WMS) Congress.